AstraZeneca (LON:AZN) Stock Price Expected to Rise, Citigroup Analyst Says

AstraZeneca (LON:AZN – Get Free Report) had its price target boosted by research analysts at Citigroup from £175 to £178 in a report issued on Tuesday,Digital Look reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s price objective indicates a potential upside of 39.50% from the company’s current price.

A number of other brokerages have also issued reports on AZN. Berenberg Bank reissued a “buy” rating and set a £160 price target on shares of AstraZeneca in a research note on Tuesday. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating and issued a £115 target price on shares of AstraZeneca in a research note on Friday, June 26th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a £180 target price on shares of AstraZeneca in a research report on Friday, June 26th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of £153.

Get AstraZeneca alerts:

Check Out Our Latest Stock Analysis on AstraZeneca

AstraZeneca Stock Down 1.0%

Shares of LON:AZN opened at £127.60 on Tuesday. The firm has a market capitalization of £197.89 billion, a PE ratio of 19.22, a price-to-earnings-growth ratio of 0.86 and a beta of 0.23. The business has a 50 day simple moving average of £134.89 and a two-hundred day simple moving average of £140.60. AstraZeneca has a 1 year low of £107.44 and a 1 year high of £157.32. The company has a debt-to-equity ratio of 71.66, a current ratio of 0.91 and a quick ratio of 0.59.

AstraZeneca Company Profile

(Get Free Report)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Further Reading

• Five stocks we like better than AstraZeneca
• AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
• Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
• Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
• Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.